The molecular biology and protein expression core is organized on the basis of the pooling of the resources and expertise of all four project leaders in the program. This centraliz&l resource provides service and assistance in molecular biology, particularly the ability to rapidly subclone the gene of interest or a mutagenized derivative into one or more expression vectors without the need for restriction digestion. The core also provides the facilities and hardware for mammalian expression, selection of stable cell lines and large scale cell growth for collection of serum-free conditioned media. The core will provide facilities for large scale isolation of recombinant proteins, the appropriate chromatography strategies and will maintain the affinity columns necessary for this activity. Assistance and facilities will also be provided for the large-scale isolation of coagulation proteins from plasma. Finally, the core will provide some quality control services particularly the quantitation of 7 carboxy-glutamic acid content to verify the integrity of expressed vitamin K- dependent proteins. The Co-Directors will be responsible for the oversight and efficient conduct of these activities and for ensuring equitable service to the projects.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL074124-05
Application #
7471420
Study Section
Special Emphasis Panel (ZHL1)
Project Start
Project End
Budget Start
2007-08-01
Budget End
2008-07-31
Support Year
5
Fiscal Year
2007
Total Cost
$224,808
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Vadivel, Kanagasabai; Kumar, Yogesh; Bunce, Matthew W et al. (2017) Interaction of factor V B-domain acidic region with its basic region and with TFPI/TFPI2: Structural insights from molecular modeling studies. Int Biol Rev 1:
Thalji, Nabil K; Camire, Rodney M (2017) Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding. Curr Opin Hematol 24:453-459
Ostertag, Eric M; Bdeir, Khalil; Kacir, Stephen et al. (2016) ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model. Transfusion 56:1775-85
Thalji, Nabil K; Ivanciu, Lacramioara; Davidson, Robert et al. (2016) A rapid pro-hemostatic approach to overcome direct oral anticoagulants. Nat Med 22:924-32
Bradford, Harlan N; Krishnaswamy, Sriram (2016) The Fragment 1 Region of Prothrombin Facilitates the Favored Binding of Fragment 12 to Zymogen and Enforces Zymogen-like Character in the Proteinase. J Biol Chem 291:11114-23
Liang, Hai Po H; Kerschen, Edward J; Basu, Sreemanti et al. (2015) Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice. Blood 126:2415-23
Pickens, Brandy; Mao, Yingying; Li, Dengju et al. (2015) Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models. Blood 125:3326-34
Zheng, X Long (2015) ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annu Rev Med 66:211-25
Baroni, M; Pavani, G; Pinotti, M et al. (2015) Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation. Biochim Biophys Acta 1854:1351-6
George, L A; Thalji, N K; Raffini, L J et al. (2015) Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L). J Thromb Haemost 13:1694-8

Showing the most recent 10 out of 101 publications